CCO Oncology Podcast

189 Épisodes

1. Precision Medicine for T-Cell Lymphomas: Expert Answers to Your Questions

   Publié: 31/01/2022
2. Multidisciplinary Overview of EGFR-Mutated NSCLC: An Expert Panel Discussion From Biomarker Testing to Managing Progressive Disease

   Publié: 26/01/2022
3. Experts Answer Questions on Current and Emerging Options for Hemophilia A Management

   Publié: 14/01/2022
4. Induction and Maintenance Therapy for Fit Patients With AML Without Targetable Mutations

   Publié: 10/01/2022
5. Strategies for Secondary AML and Emerging Therapies for AML

   Publié: 10/01/2022
6. Targeted Treatment Options for Patients With AML and FLT3 or IDH1/2 Mutations

   Publié: 10/01/2022
7. An Overview of AML and Treatment Strategies for Patients Unfit for Intensive Therapy

   Publié: 10/01/2022
8. Managing Higher-Risk and Relapsed/Refractory Myelodysplastic Syndromes: Nursing Implications

   Publié: 22/12/2021
9. Managing Lower-Risk Myelodysplastic Syndrome: Nursing Implications

   Publié: 22/12/2021
10. Key Factors Influencing Later-Line Treatment Selection for Patients With Metastatic Colorectal Cancer

    Publié: 17/12/2021
11. The Evolving Role of TKIs in First-line Treatment of Advanced HCC

    Publié: 14/12/2021
12. Expert Insight on Important Clinical Trial Data From ESGO 2021 Informing Treatment for Ovarian Cancer and Endometrial Cancers

    Publié: 23/11/2021
13. Experts Answer FAQs on Immunotherapy for Non-Small-Cell Lung Cancer

    Publié: 23/11/2021
14. Overcoming Acquired Resistance With Second-Generation TRK Inhibitors

    Publié: 09/11/2021
15. Role of TKIs in Nonadipocytic Soft Tissue Sarcoma and Advanced Osteosarcoma

    Publié: 02/11/2021
16. PARP Inhibitors in Pancreatic Cancer: Experts Discuss Importance of Testing for Biomarkers Along With Current Treatment Landscape

    Publié: 26/10/2021
17. Optimal Dosing Strategies With Regorafenib and TAS-102 for Patients With Metastatic Colorectal Cancer

    Publié: 21/10/2021
18. First-Generation TRK Inhibitors: Clinical Evidence and Indications

    Publié: 15/10/2021
19. PARP Inhibitors in Ovarian Cancer: Experts Discuss Patient Cases and the Current Paradigm

    Publié: 14/10/2021
20. Counseling Patients and Caregivers on Prophylaxis Therapy for Severe Hemophilia A

    Publié: 08/10/2021